Press Releases

  • Takeda to Sell Non-Colcrys URL Pharma, Inc. Generic Business to Sun Pharmaceutical

    18.12.2012

    Deerfield, Ill., Dec. 17, 2012 and Osaka, Japan, Dec. 18, 2012 – Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda’s wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) has entered into a definitive agreement with Caraco Pharmaceutical Laboratories, Ltd. (Caraco), a wholly-owned subsidiary of Sun Pharmaceutical Industries, Ltd. for the sale of the non-Colcrys (colchicine, USP) URL Pharma, Inc.* generic business. Read more
  • Takeda and Millennium Announce European Conditional Marketing Authorisation for ADCETRIS® (Brentuximab Vedotin)

    31.10.2012

    Osaka, Japan, and Cambridge, Mass., October 31, 2012 – Takeda Pharmaceutical Company Limited (TSE:4502, “Takeda”) and Millennium: The Takeda Oncology Company, today announced that the European Commission (EC) has granted conditional marketing authorisation for ADCETRIS® (brentuximab vedotin) for two indications: (1) the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, and (2) for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma...
  • Takeda Completes its Russian Pharmaceutical Manufacturing Facility

    12.09.2012

    • State-of-the-art facility in Yaroslavl demonstrates Takeda’s long-term commitment to the Russian market • Plant expected to be fully operational in 2014, supplying high quality tablet and sterile liquid products for the local market • €75 million investment Zurich, Switzerland, September 11, 2012 --- Takeda Pharmaceutical International GmbH (“Takeda”) today announced the completion of construction at its pharmaceutical manufacturing facility in Yaroslavl, Russia. The company has invested approximately €75 million in the 24,000m2 production plant, which is expected to be fully operational by 2014. Takeda was one of the first major international companies to have invested in high...
  • Revestive® (teduglutide) receives European marketing authorization for the treatment of adults with Short Bowel Syndrome (SBS)

    05.09.2012

    Osaka, Japan and Bedminster, NJ, September 4, 2012 --- Takeda Pharmaceutical Company Limited (TSE:4502, “Takeda”) and NPS Pharmaceuticals, Inc. (NASDAQ: NPSP, “NPS”), jointly announced today that the European Commission (EC) has granted European market authorization for the medicinal product teduglutide (trade name in Europe: Revestive®) as a once-daily treatment for adult patients with short bowel syndrome. The marketing authorization follows a positive opinion issued on June 21, 2012, by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Following the authorization, Takeda intends to provide patient access to Revestive® within Europe...
  • Takeda and Millennium Announce Positive CHMP Opinion for Conditional Approval of ADCETRIS® (brentuximab vedotin) in Europe

    23.07.2012

    Osaka, Japan, and Cambridge, Mass., July 20, 2012 – Takeda Pharmaceutical Company Limited (TSE:4502, “Takeda”) and Millennium: The Takeda Oncology Company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for conditional approval of brentuximab vedotin for two indications: (1) the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, and (2) for the treatment of adult patients with relapsed or...
  • Takeda Completes Acquisition of Brazil's Multilab

    03.07.2012

    Osaka, Japan, July 3, 2012 – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) today announced that its wholly-owned subsidiary, Takeda Farmacêutica Brasil Ltda. (São Paulo, Brazil, “Takeda Brazil”), has completed the acquisition of Multilab. The acquisition significantly strengthens Takeda’s existing presence in Brazil, positioning it as one of the top ten pharmaceutical companies in the country(1) . Multilab brings a diverse portfolio of complementary branded generics and OTC products, including Multigrip®, the country’s best-selling OTC product for cold and flu treatment in units (2) . OTC products represent approximately 30% of the total Brazilian pharmaceutical...
  • Rienso® (ferumoxytol) receives European marketing authorisation for the treatment of iron deficiency anaemia in adult chronic kidney disease patients

    25.06.2012

    London, United Kingdom and Lexington, MA, USA, June 22, 2012, and Osaka, Japan, June 25, 2012 – Takeda Pharmaceutical Company Limited (Takeda) and AMAG Pharmaceuticals, Inc. today announced the granting of marketing authorisation by the European Commission (EC) for ferumoxytol, a new intravenous (IV) iron therapy to treat iron deficiency anaemia (IDA) in adult patients with chronic kidney disease (CKD). The marketing authorisation follows a positive opinion issued on April 19, 2012, by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). With receipt of the EC decision, Takeda intends to launch ferumoxytol across Europe in the near...
  • Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive®) for patients with Short Bowel Syndrome

    25.06.2012

    Osaka, Japan June 25 and Bedminster, NJ, June 22 2012 --- Takeda Pharmaceutical Company Limited (TSE:4502, “Takeda”) and NPS Pharmaceuticals, Inc. (NASDAQ: NPSP, “NPS”), jointly announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product teduglutide (tradename in Europe: Revestive®) as a once-daily treatment for adult patients with short bowel syndrome (SBS). The marketing authorisation application was submitted in March 2011. Read more
  • Takeda Completes Acquisition of URL Pharma, Inc.

    05.06.2012

    Deerfield, Ill., June 4, 2012 and Osaka, Japan, June 5, 2012 – Takeda Pharmaceutical Company Limited (Takeda) and its wholly owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. (TPUSA), jointly announced that Takeda’s wholly owned subsidiary, Takeda America Holdings, Inc., has completed its acquisition of URL Pharma, Inc. (URL Pharma) for an upfront payment of $800 million. The deal also includes an agreement for future performance-based contingent earn out payments. With the completion of the acquisition, TPUSA will begin the integration of URL Pharma and will immediately assume responsibility for the marketing and promotion of Colcrys® (colchicine), URL Pharma’s leading product...
  • Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil

    25.05.2012

    Osaka, Japan, and São Jerônimo, Rio Grande do Sul, Brazil, May 25, 2012 – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) and Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda. (Rio Grande do Sul, Brazil, “Multilab”) today jointly announced that both parties have signed an agreement whereby Takeda Farmacêutica Brasil Ltda. (São Paulo, Brazil, “Takeda Brazil”), a wholly-owned subsidiary of Takeda, aims to acquire Multilab. Read more
  • OMONTYS® (PEGINESATIDE) INJECTION NOW AVAILABLE FOR ADULT CHRONIC KIDNEY DISEASE (CKD) PATIENTS ON DIALYSIS IN THE UNITED STATES

    25.04.2012

    Palo Alto, Calif. – April 24, 2012, and Osaka, Japan – April 25, 2012 – Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that OMONTYS® (peginesatide) Injection is now available only for use in treating anemia due to chronic kidney disease (CKD) in adult patients on dialysis. OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the dialysis patient population in the United States. OMONTYS is co-marketed by Affymax and Takeda Pharmaceuticals U.S.A (TPUSA) and distributed by TPUSA. Read more
  •  Takeda and AMAG Receive A Positive CHMP Opinion in Europe for Rienso® (ferumoxytol) for the Treatment of Iron Deficiency Anaemia in Adult Chronic Kidney Disease Patients

    23.04.2012

    London, UK, April 20, Osaka, Japan, April 23 and Lexington, MA, USA April 20 – Takeda Pharmaceutical Company Limited (Takeda) and AMAG Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for ferumoxytol, a new intravenous (IV) iron therapy with a proposed indication for the treatment of iron deficiency anaemia (IDA) in adult patients with chronic kidney disease (CKD). Read more
  • Takeda to Acquire URL Pharma

    11.04.2012

    Deerfield, Ill., Osaka, Japan, and PHILADELPHIA, April 11, 2012, – Takeda Pharmaceutical Company Limited (Takeda) and URL Pharma, Inc. (URL Pharma) jointly announced today that Takeda’s wholly-owned subsidiary, Takeda America Holdings, Inc. and URL Pharma have entered into a definitive agreement to acquire URL Pharma – a privately-held pharmaceutical company headquartered in Philadelphia, Pennsylvania, for an upfront payment of $800 million and future performance-based contingent earn out payments. Upon completion of the acquisition, URL Pharma will be managed by Takeda Pharmaceuticals U.S.A., Inc. The acquisition will contribute significantly to Takeda’s revenues, operating income,...
  • Takeda to Acquire URL Pharma

    11.04.2012

    Deerfield, Ill., Osaka, Japan, and PHILADELPHIA, April 11, 2012, – Takeda Pharmaceutical Company Limited (Takeda) and URL Pharma, Inc. (URL Pharma) jointly announced today that Takeda’s wholly-owned subsidiary, Takeda America Holdings, Inc. and URL Pharma have entered into a definitive agreement to acquire URL Pharma – a privately-held pharmaceutical company headquartered in Philadelphia, Pennsylvania, for an upfront payment of $800 million and future performance-based contingent earn out payments. Upon completion of the acquisition, URL Pharma will be managed by Takeda Pharmaceuticals U.S.A., Inc. The acquisition will contribute significantly to Takeda’s revenues, operating income,...
  • AFFYMAX AND TAKEDA ANNOUNCE FDA APPROVAL OF OMONTYS® (PEGINESATIDE) INJECTION FOR THE TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE (CKD) IN ADULT PATIENTS ON DIALYSIS

    28.03.2012

    Palo Alto, Calif. – March 27, 2012, and Osaka, Japan – March 28, 2012 - Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the U.S. Food and Drug Administration (FDA) approved OMONTYS® (peginesatide) Injection for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia to be made available to the dialysis patient population in the United States. Read more
  • Takeda Announces Establishment of Development Center in China

    09.02.2012

    Osaka, Japan, February 09, 2012—Takeda Pharmaceutical Company Limited (“Takeda”) announced today the establishment of the Takeda Shanghai Development Center (“TSDC”) within the Shanghai-based Takeda (China) Holdings Co., Ltd. (“TCH”), which is a wholly owned subsidiary of Takeda. This important step reflects Takeda’s strategic commitment to Asia and to China in particular. Takeda is now enhancing its business in China through TCH’s wholly owned subsidiaries, Takeda Pharmaceutical (China) Company Limited in Taizhou (“Takeda China”) which is responsible for marketing and sales, and Tianjin Takeda Pharmaceuticals Co., Ltd, in Tianjin (“Tianjin Takeda”) which is responsible for...
  • Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth

    18.01.2012

    OSAKA, Japan, January 18, 2012 - Takeda Pharmaceutical Company Limited (“Takeda”, TSE: 4502) announced today strategic measures to better align its global workforce and consolidate site operations in order to integrate legacy Nycomed operations, strengthen its presence in more than 70 countries, adapt to changing market conditions and maintain a focus on growth through innovation and culture, as outlined in its 2011-2013 Mid-Range Plan (MRP).

 

Takeda Pharma